Part,  Chapter, Paragraph

 1    I,     2. 10.  2|     nanoparticles, largely used in pharmaceutical and cosmetic industries
 2    I,     2. 10.  4| identification and data capture of pharmaceutical products, medical devices,
 3    I,     2. 10.  4|           chain stakeholders. Most pharmaceutical and medical device manufacturers
 4   II,     5.  1.  2|            well as the role of the pharmaceutical industry and drugs, but
 5   II,     5.  3.  7|        Health care systems and the pharmaceutical industry must jointly plan
 6   II,     5.  4.  2|          by other means, including pharmaceutical prescriptions, ambulatory
 7   II,     5.  4.  2|     estimate of prevalence and the pharmaceutical use made by diabetic patients.~
 8   II,     5.  5.  3|      marketing information for the pharmaceutical industry. The IMS-data document
 9   II,     5. 15.  3|     contribute for 1% of the total pharmaceutical expenses in a country like
10  III,    10.  2.  1|      further by a growth of online pharmaceutical suppliers and issues of
11  III,    10.  4.  2|           many applications in the pharmaceutical and agri-food industries.
12   IV,    11.  1.  5|        ensuring appropriateness of pharmaceutical care. Hospital pharmacies’
13   IV,    11.  2.  2|     availability of cost effective pharmaceutical and psycho-social treatments
14   IV,    11.  3.  2|          11.3.2. Pharmaceuticals~ ~Pharmaceutical policy varies across European
15   IV,    11.  3.  2|           in the past decades. The pharmaceutical sector has received considerable
16   IV,    11.  3.  2|            is publicly funded, the pharmaceutical sector relies heavily on
17   IV,    11.  3.  2|           HFA 2007)3. Estimates of pharmaceutical expenditure include both
18   IV,    11.  3.  2|          The public share of total pharmaceutical spending actually declined
19   IV,    11.  3.  2|           expenditure, 1990-2005~ ~Pharmaceutical policy consists of a wide
20   IV,    11.  3.  2|         governments use to control pharmaceutical expenditure is price regulation.
21   IV,    11.  3.  2|           negotiations between the pharmaceutical company and the payer, and
22   IV,    11.  3.  2|          importantly in containing pharmaceutical costs and encouraging innovation
23   IV,    11.  3.  2|          brand name drugs once the pharmaceutical patent has expired is also
24   IV,    11.  3.  2|           the growing share of the pharmaceutical market held by generics,
25   IV,    11.  3.  2|            growth.~ ~In containing pharmaceutical costs, much depends on whether
26   IV,    11.  3.  2|         remains the second largest pharmaceutical market in the world with
27   IV,    11.  3.  2|            emergence of developing pharmaceutical markets in China and India.~ ~
28   IV,    11.  3.  2|       based on price data from 181 pharmaceutical products (2005)~ ~The total
29   IV,    11.  3.  2|            Italy. Eastern European pharmaceutical markets, as represented
30   IV,    11.  6.  5|           Brogan D et al. (2006): "Pharmaceutical pricing in Europe: Weighing
31   IV,    11.  6.  5|     Mossialos E (2004): Regulating pharmaceutical prices in the European Union.
32   IV,    12.  4    |          the launch in 2006 of the Pharmaceutical Forum to better combine
33   IV,    12. 10    |         National~Yes~International pharmaceutical harmonisation~High~National~
34   IV,    12. 10    |          provides free medical and pharmaceutical care to uninsured citizens
35   IV,    12. 10    |           in 2003.~ ~International pharmaceutical harmonisation~ ~National
36   IV,    13.  8    |            Internal Market and the Pharmaceutical Forum. However, intensive